Treatment of acute bacterial exacerbations of chronic bronchitis

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 7, 2009, Pages 1173-1182

  Siempos, Ilias I ^a   Michalopoulos, Argyris ^a,b   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

lactams; Antimicrobials; Chronic obstructive pulmonary disease; Exacerbation; Haemophilus influenzae; Moraxella catarrhalis; Moxifloxacin; Pseudomonas aeruginosa; Respiratory tract infections; Streptococcus pneumonia

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; BRONCHODILATING AGENT; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DIRITHROMYCIN; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; FROPENEM; GARENOXACIN; GEMIFLOXACIN; IPRATROPIUM BROMIDE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PIVAMPICILLIN; PROCALCITONIN; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; ROXITHROMYCIN; UNINDEXED DRUG; ANTIINFECTIVE AGENT;

ACUTE EXACERBATION OF CHRONIC BRONCHITIS; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE EXACERBATION; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; LOWER RESPIRATORY TRACT INFECTION; OXYGEN THERAPY; PHYSIOTHERAPY; REVIEW; SPUTUM ANALYSIS; SURVIVAL; TREATMENT DURATION; ACUTE DISEASE; BRONCHITIS; CHRONIC DISEASE; PATIENT CARE;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; BRONCHITIS; BRONCHODILATOR AGENTS; CHRONIC DISEASE; EPISODE OF CARE; HUMANS;

EID: 67649516069     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902907734     Document Type: Review

References (75)

1. Rabe KF, Hurd S, Anzueto A, et al. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555
2. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007;131:696-704 (Pubitemid 46446859)
3. Llor C, Molina J, Naberan K, et al.; EVOCA study group. Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare. Int J Clin Pract 2008;62:585-592 (Pubitemid 351348035)
4. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease: the SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154:959-967
5. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-931 (Pubitemid 41598207)
6. Simoens S, Decramer M. Pharmacoeconomics of the management of acute exacerbations of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2007;8:633-648 (Pubitemid 46547016)
7. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:554-564 (Pubitemid 47547851)
8. MacIntyre N, Huang YC. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:530-535 (Pubitemid 351669182)
9. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204 •• This important study demonstrated that administration of antibiotics is beneficial in patients with acute exacerbations of chronic bronchitis presenting with at least two of the following symptoms: increased dyspnea, increased sputum production and presence of purulent sputum. (Pubitemid 17009877)
10. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-1121 (Pubitemid 43726892)
11. Puhan MA, Vollenweider D, Latshang T, et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res 2007;8:30
12. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;2:CD004403 • This comprehensive meta-analysis of randomized controlled trials revealed that in exacerbations of chronic bronchitis with increased cough and sputum purulence antibiotics, regardless of choice, reduce the risk of short-term mortality by 77% and the risk of treatment failure by 53%.
13. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273:957-960
14. Roede BM, Bresser P, Bindels PJ, et al. Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax 2008;63:968-973
15. Roede BM, Bresser P, Prins JM, et al. Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD. Eur Respir J 2009;33:282-288
16. Puhan MA, Vollenweider D, Steurer J, et al. Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbations with antibiotics? A systematic review. BMC Med 2008;6:28
17. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000;117:1638-1645 (Pubitemid 30413357)
18. Allegra L, Blasi F, Diano P, et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med 2005;99:742-747 (Pubitemid 40631301)
19. Soler N, Agustí C, Angrill J, et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007;62:29-35 •• This study demonstrated that patient-reported sputum purulence is a reasonable indicator of distal airway bacterial infection in patients with acute exacerbations of chronic bronchitis.
20. Lode H, Allewelt M, Balk S, et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007;35:143-149 (Pubitemid 46932325)
21. Burley CJ, Masterton RG, Lovell DP. Indicators of bacterial infection in patients with acute exacerbation of chronic bronchitis for application in clinical trials of antibacterial drugs. J Infect 2007;55:226-232 (Pubitemid 47244922)
22. Nseir S, Cavestri B, Di Pompeo C, et al. Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. Respiration 2008;76:253-260
23. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin guidance with standard therapy. Chest 2007;131:9-19 • This study showed that measurement of serum procalcitonin concentration as a means to guide antimicrobial treatment in patients with acute exacerbations of chronic bronchitis may lead to reduced total antibiotic exposure in such patients. (Pubitemid 46122969)
24. Balter MS, La Forge J, Low DE, et al.; Canadian Thoracic Society; Canadian Infectious Disease Society. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003;10:3B-32B
25. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs 2008;68:1841-1854
26. Grammatikos AP, Siempos II, Michalopoulos A, Falagas ME. Optimal duration of the antimicrobial treatment of ventilator-acquired pneumonia. Expert Rev Anti Infect Ther 2008;6:861-866
27. Falagas ME, Avgeri SG, Matthaiou DK, et al. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother 2008;62:442-450
28. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006;174:84-93 (Pubitemid 43955248)
29. Korbila IP, Manta KG, Siempos II, et al. Penicillins vs trimethoprim based regimens for acute bacterial exacerbations of chronic bronchitis: a meta-analysis of randomized controlled trials. Can Fam Physician 2009;55:60-67
30. Woodhead M, Blasi F, Ewig S, et al. European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-1180
31. Sethi S. Moxifloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2005;41:S177-85 (Pubitemid 40962488)
32. Destache CJ, Dewan N, O'Donohue WJ, et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;43:107-113 (Pubitemid 29123509)
33. Nseir S, Ader F. Prevalence and outcome of severe chronic obstructive pulmonary disease exacerbations caused by multidrug-resistant bacteria. Curr Opin Pulm Med 2008;14:95-100 (Pubitemid 351323158)
34. Dimopoulos G, Siempos II, Korbila IP, et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest 2007;132:447-55 •• This meta-analysis of randomized controlled trials showed that administration of 'old' antimicrobial agents, such as amoxicillin and related drugs, cannot be any more recommended for use in exacerbations of chronic bronchitis in the era of emerging antimicrobial resistance among the pathogens responsible for these exacerbations.
35. Moss M, Wilkes D, Ware LB. Clinical year in review II: pulmonary infections in the immunocompetent host, issues in the training of fellows and residents, asthma, and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:745-750
36. Siempos II, Dimopoulos G, Korbila IP, et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. Eur Respir J 2007;29:1127-1137 • By including data from 7405 patients with acute exacerbations of chronic broncithis, this meta-analysis showed that, although there is no difference between macrolides, quinolones and amoxicillin/clavulanic acid regarding their clinical success, quinolones were associated with better microbiological success and fewer recurrences than macrolides. (Pubitemid 46895371)
37. Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of patients with community acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008;179:1269-1277
38. Wilson R, Jones P, Schaberg T, et al.; MOSAIC Study Group. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006;61:337-342
39. Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone. Expert Opin Pharmacother 2008;9:1755-1772
40. European Medicines Agency: Press office. European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines. Doc. Ref. EMEA/CHMP/382927/2008
41. Blondeau JM, Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert Opin Pharmacother 2004;5:1117-1152 (Pubitemid 38702342)
42. Wilson R, Schentag JJ, Ball P, Mandell L; 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002;24:639-652
43. Cazzola M, Salvatori E, Dionisio P, Allegra L. Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis. Pulm Pharmacol Ther 2006;19(Suppl 1):30-37 (Pubitemid 43068596)
44. Concia E, Allegranzi B, Ciottoli GB, et al. Penetration of orally administered prulifloxacin into human lung tissue. Clin Pharmacokinet 2005;44:1287-1294 (Pubitemid 41832569)
45. Grassi C, Salvatori E, Rosignoli MT, Dionisio P. Prulifloxacin Study Group. Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis. Respiration 2002;69:217-222 (Pubitemid 34827835)
46. Takagi H, Tanaka K, Tsuda H, Kobayashi H. Clinical studies of garenoxacin. Int J Antimicrob Agents 2008;32:468-474
47. Van Wart S, Phillips L, Ludwig EA, et al. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2004;48:4766-4777 (Pubitemid 39577683)
48. Andrews J, Honeybourne D, Jevons G, et al. Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects. J Antimicrob Chemother 2003;51:727-730 (Pubitemid 36336171)
49. Panpanich R, Lerttrakarnnon P, Laopaiboon M. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst Rev 2008;1:CD001954 (Pubitemid 351807750)
50. Blasi F, Aliberti S, Tarsia P. Clinical applications of azithromycin microspheres in respiratory tract infections. Int J Nanomedicine 2007;2:551-559
51. Martinez FJ. Acute exacerbation of chronic bronchitis: expanding short-course therapy. Int J Antimicrob Agents 2005;26(Suppl 3):156-163
52. Guay DR, Gustavson LE, Devcich KJ, et al. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin Ther 2001;23:566-577 (Pubitemid 32411407)
53. Halpern MT, Cifaldi MA, Schmier JK. Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections. COPD 2005;2:217-223 (Pubitemid 40993296)
54. Bishai WR. Macrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: a focus on clarithromycin. Expert Rev Anti Infect Ther 2006;4:405-416 (Pubitemid 43905463)
55. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139-1147
56. Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007;369:482-490 (Pubitemid 46209315)
57. Anzueto A, Bishai WR, Pottumarthy S. Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis. Diagn Microbiol Infect Dis 2007;57(Suppl 3):31-38 (Pubitemid 46350897)
58. Sader HS, Jones RN. Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections. Expert Rev Anti Infect Ther 2007;5:29-43
59. Joseph J, Rodvold KA. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin Pharmacother 2008;9:561-575
60. Siempos II, Vardakas KZ, Manta KG, Falagas ME. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J 2007;29:548-560 (Pubitemid 46372104)
61. Burkhardt O, Derendorf H, Welte T. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother 2007;8:237-256 (Pubitemid 46206625)
62. Gettig JP, Crank CW, Philbrick AH. Faropenem medoxomil. Ann Pharmacother 2008;42:80-90
63. McCrory DC, Brown CD. Anti-cholinergic bronchodilators versus β2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;4:CD003900
64. Kirsten DK, Wegner RE, Jörres RA, Magnussen H. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest 1993;104:1101-1107 (Pubitemid 23306061)
65. Barr RG, Rowe BH, Camargo CA. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomized trials. BMJ 2003;327:643 (Pubitemid 37153554)
66. Stoller JK. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;341:988-994 (Pubitemid 34983250)
67. Lindenauer PK, Pekow P, Gao S, et al. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006;144:894-903 (Pubitemid 46768129)
68. Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2008;133:756-766
69. Wood-Baker RR, Gibson PG, Hannay M, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;1:CD001288
70. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59:1-232
71. Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002;165:698-703 (Pubitemid 34194760)
72. McCrory DC, Brown C, Gelfand SE, Back PB. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001;119:1190-1209 (Pubitemid 32679450)
73. Zuin R, Palamidese A, Negrin R, et al. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig 2005;25:401-408 (Pubitemid 41019987)
74. Siempos II, Vardakas KZ, Kopterides P, Falagas ME. Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 2008;62:661-668
75. Ram FSF, Picot J, Lightowler J, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004;3:CD004104